zabmedvestnikЗабайкальский медицинский вестникTransbaikalian Medical Bulletin1998-6173Читинская государственная медицинская академия10.52485/19986173_2025_3_118zabmedvestnik-282Research ArticleНАУЧНЫЕ ОБЗОРЫSCIENTIFIC REVIEWSМЕДИКАМЕНТОЗНАЯ КОРРЕКЦИЯ НАРУШЕНИЙ ГЛИКОКАЛИКСА ПРИ ОСЛОЖНЕНИЯХ САХАРНОГО ДИАБЕТАDRUG CORRECTION OF GLYCOCALYX DISORDERS IN COMPLICATIONS OF DIABETES MELLITUShttps://orcid.org/0000-0002-0082-1971ВоробьёваА. П.VorobyevaA. P.

Воробьёва Анна Павловна, врач анестезиолог-реаниматолог палат реанимации и интенсивной терапии, ассистент кафедры скорой и неотложной медицинской помощи с курсом ДПО

355017, г. Ставрополь, ул. Мира, 310

355002, г. Ставрополь, ул. Пономарева, 5

Vorobyeva A.P., anesthesiologist-resuscitator of the Intensive Care and Intensive Care Wards, Assistant of the Department of Emergency Medical Care with a course of Additional Postgraduate Education

310 Mira St., Stavropol, 355017

5 Ponomareva St., Stavropo'l, 355002

a.v.955@yandex.ruhttps://orcid.org/0000-0003-4705-3823БыковЮ. В.BykovYu. V.

Быков Юрий Витальевич, к.м.н., доцент кафедры анестезиологии, реаниматологии и скорой медицинской помощи

355017, г. Ставрополь, ул. Мира, 310

Bykov Yu.V., Candidate of Medical Sciences, Associate Professor of the Department of Anesthesiology, Resuscitation and Emergency Medicine

310 Mira St., Stavropol, 355017

yubykov@gmail.comhttps://orcid.org/0000-0002-6892-3552БатуринВ. А.BaturinV. A.

Батурин Владимир Александрович, д.м.н., профессор, заведующий кафедрой клинической фармакологии, с курсом ДПО

355017, г. Ставрополь, ул. Мира, 310

Baturin V.A., Doctor of Medical Sciences, Professor, Head of the Department of Clinical Pharmacology, with a course of Additional Postgraduate Education

310 Mira St., Stavropol, 355017

prof.baturin@gmail.comhttps://orcid.org/0009-0008-4009-1783МассоровВ. В.MassorovV. V.

Массоров Владислав Викторович, врач анестезиолог-реаниматолог палат реанимации и интенсивной терапии

355002, г. Ставрополь, ул. Пономарева, 5

Massorov V.V., anesthesiologist-resuscitator of the Intensive Care and Intensive Care Wards

5 Ponomareva St., Stavropo'l, 355002

vladislav.massorov@yandex.ruФГБОУ ВО «Ставропольский государственный медицинский университет» Министерства здравоохранения РФ; ГБУЗ СК «Городская детская клиническая больница им. Г.К. Филиппского»,РоссияStavropol State Medical University; City Children's Clinical Hospital named after G.K. FilippskyRussian FederationФГБОУ ВО «Ставропольский государственный медицинский университет» Министерства здравоохранения РФРоссияStavropol State Medical UniversityRussian FederationГБУЗ СК «Городская детская клиническая больница им. Г.К. Филиппского»РоссияCity Children's Clinical Hospital named after G.K. FilippskyRussian Federation20250211202503118128Copyright © Воробьёва А.П., Быков Ю.В., Батурин В.А., Массоров В.В., 20252025Воробьёва А.П., Быков Ю.В., Батурин В.А., Массоров В.В.Vorobyeva A.P., Bykov Y.V., Baturin V.A., Massorov V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.zabmedvestnik.ru/jour/article/view/282

Сахарный диабет (СД) представляет собой одну из наиболее распространённых эндокринных патологий, сопровождающуюся множеством осложнений, включая болезни сердечно-сосудистой системы, нефропатию и невропатию. Одним из ключевых механизмов, вовлеченных в патогенез этих осложнений, является повреждение эндотелиального гликокаликса (ЭГ) — тонкого слоя углеводов на поверхности эндотелиальных клеток, играющего важную роль в поддержании целостности сосудистой стенки и регуляции воспалительных процессов. В последние годы возрос интерес к медикаментозной коррекции нарушений ЭГ как возможному направлению в лечении осложнений СД. В этой статье будут рассмотрены существующие подходы и препараты, влияющие на состояние ЭГ, опираясь на данные современных исследований.

Diabetes mellitus (DM) is a common endocrine disorder that can lead to various complications, including cardiovascular diseases, nephropathy, and neuropathy. These complications are associated with damage to the endothelial glycocalyx (EG), which is a layer of carbohydrates that covers the surface of endothelial cells and plays an important role in maintaining vascular integrity and regulating inflammation. In recent years, researchers have shown interest in targeting EG as a potential treatment for DM complications. This article will discuss existing approaches and medications that can affect EG, based on recent studies.

сахарный диабетдиабетические осложненияэндотелиальный гликокаликсмедикаментозная коррекцияdiabetes mellitusdiabetic complicationsendothelial glycocalyxdrug correctionReferencesHarreiter J., Roden M. Diabetes mellitus – Definition, Klassifikation, Diagnose, Screening und Prävention. Wien Klin Wochenschr. 2023; 135: 7–17. doi:10.1007/s00508-022-02122-y.Harreiter J., Roden M. Diabetes mellitus – Definition, Klassifikation, Diagnose, Screening und Prävention. Wien Klin Wochenschr. 2023. 135: 7–17. doi:10.1007/s00508-022-02122-y.American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2020. 43: 14–31. doi:10.2337/dc20-S002.American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2020. 43: 14– 31. doi:10.2337/dc20-S002.Rosen C., Ingelfinger J. Traveling down the long road to type 1 diabetes mellitus prevention. N Engl J Med. 2019. 381 (7): 666–667. doi:10.1056/NEJMe1907458.Rosen C., Ingelfinger J. Traveling down the long road to type 1 diabetes mellitus prevention. N Engl J Med. 2019. 381 (7): 666–667. doi:10.1056/NEJMe1907458.Wei J., Tian J., Tang C., et al. The Influence of Different Types of Diabetes on Vascular Complications. J Diabetes Res. 2022. 2022: 3448618. doi:10.1155/2022/3448618.Wei J., Tian J., Tang C., et al. The Influence of Different Types of Diabetes on Vascular Complications. J Diabetes Res. 2022. 2022: 3448618. doi:10.1155/2022/3448618.Дедов И.И., Шестакова М.В., Викулова О.К., и соавт. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за 2010-2022 гг. Сахарный диабет. 2023. 26 (2): 104–123. doi:10.14341/DM13035.Dedov I.I., Shestakova M.V., Vikulova O.K., et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Diabetes Register for 2010-2022. Sakharnyy Diabet. 2023. 26 (2): 104–123. doi:10.14341/DM13035. In Russian.Li H., Lu W., Wang A., et al. Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from Global Burden of Disease 2017. J Diabetes Investig. 2021. 12 (3): 346–356. doi:10.1111/jdi.13355.Li H., Lu W., Wang A., et al. Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from Global Burden of Disease 2017. J Diabetes Investig. 2021. 12 (3): 346–356. doi:10.1111/jdi.13355.Cole J., Florez J. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020. 16 (7): 377–390. doi:10.1038/s41581-020-0278-5.Cole J., Florez J. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020. 16 (7): 377–390. doi:10.1038/s41581-020-0278-5.Пыхова Е.Б., Степанова Т.В., Лагутина Д.Д., и соавт. Роль сахарного диабета в возникновении и развитии эндотелиальной дисфункции. Проблемы эндокринологии. 2020. 66 (1): 47–55. doi:10.14341/probl12425.Pykhova E.B., Stepanova T.V., Lagutina D.D., et al. The role of diabetes mellitus in the occurrence and development of endothelial dysfunction. Probl Endokrinol (Mosk). 2020. 66 (1): 47–55. In Russian.Thota L., Chignalia A. The role of the glypican and syndecan families of heparan sulfate proteoglycans in cardiovascular function and disease. Am J Physiol Cell Physiol. 2022. 323 (4): 52–60. doi:10.1152/ajpcell.00018.2022.Thota L., Chignalia A. The role of the glypican and syndecan families of heparan sulfate proteoglycans in cardiovascular function and disease. Am J Physiol Cell Physiol. 2022. 323 (4): 52–60. doi:10.1152/ajpcell.00018.2022.Shurer C., Kuo J., Roberts L., et al. Physical Principles of Membrane Shape Regulation by the Glycocalyx. Cell. 2019. 177 (7): 1757–1770. doi:10.1016/j.cell.2019.04.017.Shurer C., Kuo J., Roberts L., et al. Physical Principles of Membrane Shape Regulation by the Glycocalyx. Cell. 2019. 177 (7): 1757–1770. doi:10.1016/j.cell.2019.04.017.Воробьёва А.П., Быков Ю.В., Батурин В.А. и соавт. Нарушения гликокаликса при критических состояниях: патофизиологические и клинические аспекты. Якутский медицинский журнал. 2024. № 1 (85). С. 77–81.Vorobyeva A.P., Bykov Yu.V., Baturin V.A., et al. (2024). Glycocalyx impairment in critical conditions: pathophysiological and clinical aspects. Yakut Medical Journal, (1) 85, 77–81. In Russian.Воробьёва А.П., Быков Ю.В., Батурин В.А. и соавт. Роль гликокаликса в патогенезе осложнений сахарного диабета. Забайкальский медицинский вестник. 2024. № 2. С. 80–89.Vorobyeva A.P., Bykov Yu.V., Baturin V.A., et al. (2024). The role of the glycocalyx in the pathogenesis of diabetes mellitus complications. Transbaikal Medical Bulletin, 2, 80-89. In Russian.Iliff A., Xu X.Z.S. A mechanosensitive GPCR that detects the bloody force. Cell. 2018. 173 (3): 542–544. doi:10.1016/j.cell.2018.04.001.Iliff A., Xu X.Z.S. A mechanosensitive GPCR that detects the bloody force. Cell. 2018. 173 (3): 542–544. doi:10.1016/j.cell.2018.04.001.Krüger-Genge A., Blocki A., Franke R.P., et al. Vascular endothelial cell biology: An update. Int J Mol Sci. 2019. 20 (18): 4411. doi:10.3390/ijms20184411.Krüger-Genge A., Blocki A., Franke R.P., et al. Vascular endothelial cell biology: An update. Int J Mol Sci. 2019. 20 (18): 4411. doi:10.3390/ijms20184411.Fan J., Sun Y., Xia Y., et al. Endothelial surface glycocalyx (ESG) components and ultra-structure revealed by stochastic optical reconstruction microscopy (STORM). Biorheology. 2019. 56: 77–88. doi:10.3233/BIR-180204.Fan J., Sun Y., Xia Y., et al. Endothelial surface glycocalyx (ESG) components and ultra-structure revealed by stochastic optical reconstruction microscopy (STORM). Biorheology. 2019. 56: 77–88. doi:10.3233/BIR-180204.Suzuki A., Tomita H., Okada H. Form follows function: the endothelial glycocalyx. Transl Res. 2022. 247: 158–167. doi:10.1016/j.trsl.2022.03.014.Suzuki A., Tomita H., Okada H. Form follows function: the endothelial glycocalyx. Transl Res. 2022. 247: 158–167. doi:10.1016/j.trsl.2022.03.014.Wang G., Tiemeier G., van den Berg B.M., et al. Endothelial Glycocalyx Hyaluronan: Regulation and Role in Prevention of Diabetic Complications. Am J Pathol. 2020. 190 (4): 781–790. doi:10.1016/j.ajpath.2019.07.022.Wang G., Tiemeier G., van den Berg B.M., et al. Endothelial Glycocalyx Hyaluronan: Regulation and Role in Prevention of Diabetic Complications. Am J Pathol. 2020. 190 (4): 781–790. doi:10.1016/j.ajpath.2019.07.022.Воробьёва А.П., Быков Ю.В., Батурин В.А. и соавт. Маркеры повреждения гликокаликса при осложнениях сахарного диабета. Современные проблемы науки и образования. 2023. № 4. С. 145.Vorobyeva A.P., Bykov Yu.V., Baturin V.A., et al. (2023). Markers of glycocalyx damage in diabetes mellitus complications. Modern Problems of Science and Education, (4), 145. In Russian.van den Berg B.M., Wang G., Boels M., et al. Glomerular Function and Structural Integrity Depend on Hyaluronan Synthesis by Glomerular Endothelium. J Am Soc Nephrol. 2019. 30 (10): 1886–1897. doi:10.1681/ASN.2019020192.van den Berg B.M., Wang G., Boels M., et al. Glomerular Function and Structural Integrity Depend on Hyaluronan Synthesis by Glomerular Endothelium. J Am Soc Nephrol. 2019. 30 (10): 1886–1897. doi:10.1681/ASN.2019020192.Queisser K., Mellema R., Petrey A. Hyaluronan and its receptors as regulatory molecules of the endothelial interface. J Histochem Cytochem. 2021. 69 (1): 25–34. doi:10.1369/0022155420954296.Queisser K., Mellema R., Petrey A. Hyaluronan and its receptors as regulatory molecules of the endothelial interface. J Histochem Cytochem. 2021. 69 (1): 25–34. doi:10.1369/0022155420954296.Wang G., Kostidis S., Tiemeier G., et al. Shear Stress Regulation of Endothelial Glycocalyx Structure Is Determined by Glucobiosynthesis. Arterioscler Thromb Vasc Biol. 2020. 40 (2): 350–364. doi:10.1161/ATVBAHA.119.313399.Wang G., Kostidis S., Tiemeier G., et al. Shear Stress Regulation of Endothelial Glycocalyx Structure Is Determined by Glucobiosynthesis. Arterioscler Thromb Vasc Biol. 2020. 40 (2): 350–364. doi:10.1161/ATVBAHA.119.313399.Hirota T., Levy J., Iba T. The influence of hyperglycemia on neutrophil extracellular trap formation and endothelial glycocalyx damage in a mouse model of type 2 diabetes. Microcirculation. 2020. 27: e12617. doi:10.1111/micc.12617.Hirota T., Levy J., Iba T. The influence of hyperglycemia on neutrophil extracellular trap formation and endothelial glycocalyx damage in a mouse model of type 2 diabetes. Microcirculation. 2020. 27: e12617. doi:10.1111/micc.12617.Aggarwal H., Pathak P., Kumar Y., et al. Modulation of insulin resistance, dyslipidemia and serum metabolome in iNOS knockout mice following treatment with nitrite, metformin, pioglitazone, and a combination of ampicillin and neomycin. Int J Mol Sci. 2021. 23 (1): 195. doi:10.3390/ijms23010195.Aggarwal H., Pathak P., Kumar Y., et al. Modulation of insulin resistance, dyslipidemia and serum metabolome in iNOS knockout mice following treatment with nitrite, metformin, pioglitazone, and a combination of ampicillin and neomycin. Int J Mol Sci. 2021. 23 (1): 195. doi:10.3390/ijms23010195.Воробьёва А.П., Быков Ю.В., Батурин В.А., Муравьёва А.А. Медикаментозная коррекция повреждений гликокаликса. Забайкальский медицинский вестник. 2023. № 2. С. 131–140.Vorobyeva A.P., Bykov Yu.V., Baturin V.A., Muravyeva A.A. (2023). Pharmacological correction of glycocalyx injuries. Transbaikal Medical Bulletin, (2), 131–140. In Russian.Ding Y., Zhou Y., Ling P., et al. Metformin in cardiovascular diabetology: A focused review of its impact on endothelial function. Theranostics. 2021. 11: 9376–9396. doi:10.7150/thno.64706.Ding Y., Zhou Y., Ling P., et al. Metformin in cardiovascular diabetology: A focused review of its impact on endothelial function. Theranostics. 2021. 11: 9376–9396. doi:10.7150/thno.64706.DeFronzo R., Reeves W., Awad A.S. Pathophysiology of diabetic kidney disease: Impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021. 17: 319–334. doi:10.1038/s41581-021-00393-8.DeFronzo R., Reeves W., Awad A.S. Pathophysiology of diabetic kidney disease: Impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021. 17: 319–334. doi:10.1038/s41581-021-00393-8.Heerspink H., Perco P., Mulder S., et al. Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019. 62: 1154–1166. doi:10.1007/s00125-019-4859-4.Heerspink H., Perco P., Mulder S., et al. Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019. 62: 1154–1166. doi:10.1007/s00125-019-4859-4.Chang M., Liu G., Wang Y., et al. Long non-coding RNA LINC00299 knockdown inhibits ox-LDLinduced T/G HA-VSMC injury by regulating miR-135a-5p/XBP1 axis in atherosclerosis. Panminerva Med. 2022. 64: 38–47. doi:10.23736/S0031-0808.20.03942-7.Chang M., Liu G., Wang Y., et al. Long non-coding RNA LINC00299 knockdown inhibits ox-LDLinduced T/G HA-VSMC injury by regulating miR-135a-5p/XBP1 axis in atherosclerosis. Panminerva Med. 2022. 64: 38–47. doi:10.23736/S0031-0808.20.03942-7.Targosz-Korecka M., Malek-Zietek K.E., Kloska D., et al. Metformin attenuates adhesion between cancer and endothelial cells in chronic hyperglycemia by recovery of the endothelial glycocalyx barrier. Biochim Biophys Acta Gen Subj. 2020. 1864 (4): 129533. doi:10.1016/j.bbagen.2020.129533.Targosz-Korecka M., Malek-Zietek K.E., Kloska D., et al. Metformin attenuates adhesion between cancer and endothelial cells in chronic hyperglycemia by recovery of the endothelial glycocalyx barrier. Biochim Biophys Acta Gen Subj. 2020. 1864 (4): 129533. doi:10.1016/j.bbagen.2020.129533.Dogné S., Flamion B., Caron N. Endothelial Glycocalyx as a Shield Against Diabetic Vascular Complications: Involvement of Hyaluronan and Hyaluronidases. Arterioscler Thromb Vasc Biol. 2018. 38 (7): 1427–1439. doi:10.1161/ATVBAHA.118.310839.Dogné S., Flamion B., Caron N. Endothelial Glycocalyx as a Shield Against Diabetic Vascular Complications: Involvement of Hyaluronan and Hyaluronidases. Arterioscler Thromb Vasc Biol. 2018. 38 (7): 1427–1439. doi:10.1161/ATVBAHA.118.310839.Gamez M., Elhegni H.E., Fawaz S. Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes. Cardiovasc Diabetol. 2024. 23: 50. doi:10.1186/s12933-024-02133-1.Gamez M., Elhegni H.E., Fawaz S. Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes. Cardiovasc Diabetol. 2024. 23: 50. doi:10.1186/s12933-024-02133-1.Amjad M.V. Dendrimers in targeted delivery of anticancer drugs: achievements, problems and prospects for further research. Pharm Pharmacol. 2021. 1.Amjad M.V. Dendrimers in targeted delivery of anticancer drugs: achievements, problems and prospects for further research. Pharm Pharmacol. 2021;1.Machin D., Trott D., Gogulamudi V., et al. Glycocalyx-targeted therapy ameliorates age-related arterial dysfunction. Geroscience. 2023. Online ahead of print. doi:10.1007/s11357-023-00745-1.Machin D., Trott D., Gogulamudi V., et al. Glycocalyx-targeted therapy ameliorates age-related arterial dysfunction. Geroscience. 2023. Online ahead of print. doi:10.1007/s11357-023-00745-1.Carroll B.J., Piazza G., Goldhaber S.Z. Sulodexide in venous disease. J Thromb Haemost. 2019. 17 (1): 31–38. doi:10.1111/jth.14324.Carroll B.J., Piazza G., Goldhaber S.Z. Sulodexide in venous disease. J Thromb Haemost. 2019. 17 (1): 31–38. doi:10.1111/jth.14324.Roshan-Milani S., Khalilpour J., Abdollahzade F.A. The heparanase inhibitor (sulodexide) decreases urine glycosaminoglycan excretion and mitigates functional and histological renal damages in diabetic rats. Acta Med Bulg. 2019. 46 (2): 41–46. doi:10.2478/amb-2019-0017.Roshan-Milani S., Khalilpour J., Abdollahzade F.A. The heparanase inhibitor (sulodexide) decreases urine glycosaminoglycan excretion and mitigates functional and histological renal damages in diabetic rats. Acta Med Bulg. 2019. 46 (2): 41–46. doi:10.2478/amb-2019-0017.Li T., Liu C. Sulodexide recovers endothelial function through reconstructing glycocalyx in the ballooninjury rat carotid artery model. Int Angiol. 2018. 37: 72.Li T., Liu C. Sulodexide recovers endothelial function through reconstructing glycocalyx in the ballooninjury rat carotid artery model. Int Angiol. 2018. 37: 72.Song J.W., Zullo J.A., Liveris D., et al. Therapeutic restoration of endothelial glycocalyx in sepsis. J Pharmacol Exp Ther. 2017. 361 (1): 115–121. doi:10.1124/jpet.116.239509.Song J.W., Zullo J.A., Liveris D., et al. Therapeutic restoration of endothelial glycocalyx in sepsis. J Pharmacol Exp Ther. 2017. 361 (1): 115–121. doi:10.1124/jpet.116.239509.Ligi D., Benitez S., Croce L., et al. Electronegative LDL induces MMP-9 and TIMP-1 release in monocytes through CD14 activation: inhibitory effect of glycosaminoglycan sulodexide. Biochim Biophys Acta Mol Basis Dis. 2018. 1864 (12): 3559–3567. doi:10.1016/j.bbadis.2018.09.022.Ligi D., Benitez S., Croce L., et al. Electronegative LDL induces MMP-9 and TIMP-1 release in monocytes through CD14 activation: inhibitory effect of glycosaminoglycan sulodexide. Biochim Biophys Acta Mol Basis Dis. 2018. 1864 (12): 3559–3567. doi:10.1016/j.bbadis.2018.09.022.De Felice F., Megiorni F., Pietrantoni I., et al. Sulodexide counteracts endothelial dysfunction induced by metabolic or non-metabolic stresses through activation of the autophagic program. Eur Rev Med Pharmacol Sci. 2019. 23 (6): 2669–2680. doi:10.26355/eurrev_201903_17415.De Felice F., Megiorni F., Pietrantoni I., et al. Sulodexide counteracts endothelial dysfunction induced by metabolic or non-metabolic stresses through activation of the autophagic program. Eur Rev Med Pharmacol Sci. 2019. 23 (6): 2669-2680. doi:10.26355/eurrev_201903_17415.Giurdanella G., Lazzara F., Caporarello N., et al. Sulodexide prevents activation of the PLA2/COX-2/VEGF inflammatory pathway in human retinal endothelial cells by blocking the effect of AGE/RAGE. Biochem Pharmacol. 2017. 142: 145–154. doi:10.1016/j.bcp.2017.06.130.Giurdanella G., Lazzara F., Caporarello N., et al. Sulodexide prevents activation of the PLA2/COX-2/VEGF inflammatory pathway in human retinal endothelial cells by blocking the effect of AGE/RAGE. Biochem Pharmacol. 2017. 142: 145–154. doi:10.1016/j.bcp.2017.06.130.Matuska J., Benova K. Development of wall stiffness parameters in diabetes mellitus type II—evaluation of therapeutic effect of sulodexide vs naftidrofuryl: an open controlled 2-year study. Vasa-Eur J Vasc Med. 2017. 46: 30. doi:10.1024/0301-1526/a000651.Matuska J., Benova K. Development of wall stiffness parameters in diabetes mellitus type II—evaluation of therapeutic effect of sulodexide vs naftidrofuryl: an open controlled 2-year study. Vasa-Eur J Vasc Med. 2017. 46: 30. doi:10.1024/0301-1526/a000651.Сокологорский С.В., Овечкин А.М., Политов М.Е., Буланова Е.Л. Восстановление гликокаликса! Есть ли возможности? Анестезиология и реаниматология. 2022. 1: 102–110. doi:10.17116/anaesthesiology2022011102.Sokologorsky S.V., Ovechkin A.M., Politov M.E., Bulanova E.L. Restore glycocalyx! Are there any possibilities? Anesteziol Reanimatol. 2022. 1: 102–110. doi:10.17116/anaesthesiology2022011102. In Russian.Bignamini A.A., Chebil A., Gambaro G., Matuška J. Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis. Adv Ther. 2021. 38 (3): 1483–1513. doi:10.1007/s12325-021-01620-1.Bignamini A.A., Chebil A., Gambaro G., Matuška J. Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis. Adv Ther. 2021. 38 (3): 1483–1513. doi:10.1007/s12325-021-01620-1.Li Z., Wu N., Wang J., et al. Low molecular weight fucoidan restores diabetic endothelial glycocalyx by targeting neuraminidase 2: A new therapy target in glycocalyx shedding. Br J Pharmacol. 2024. 181 (9): 1404–1420. doi:10.1111/bph.16288.Li Z., Wu N., Wang J., et al. Low molecular weight fucoidan restores diabetic endothelial glycocalyx by targeting neuraminidase 2: A new therapy target in glycocalyx shedding. Br J Pharmacol. 2024. 181 (9): 1404–1420. doi:10.1111/bph.16288.Zahan M.S., Hasan A., Rahman M.H., et al. Protective effects of fucoidan against kidney diseases: Pharmacological insights and future perspectives. Int J Biol Macromol. 2022. 209 (Pt B): 2119–2129. doi:10.1016/j.ijbiomac.2022.04.192.Zahan M.S., Hasan A., Rahman M.H., et al. Protective effects of fucoidan against kidney diseases: Pharmacological insights and future perspectives. Int J Biol Macromol. 2022. 209 (Pt B): 2119–2129. doi:10.1016/j.ijbiomac.2022.04.192.Heimerl M., Sieve I., Ricke-Hoch M., et al. Neuraminidase-1 promotes heart failure after ischemia/reperfusion injury by affecting cardiomyocytes and invading monocytes/macrophages. Basic Res Cardiol. 2020. 115:62.Heimerl M., Sieve I., Ricke-Hoch M., et al. Neuraminidase-1 promotes heart failure after ischemia/reperfusion injury by affecting cardiomyocytes and invading monocytes/macrophages. Basic Res Cardiol. 2020. 115: 62.Foote C., Ramirez-Perez F., Smith J., et al. Neuraminidase inhibition improves endothelial function in diabetic mice. Am J Physiol Heart Circ Physiol. 2023. 325 (6): 1337–1353. doi:10.1152/ajpheart.00337.2023.Foote C., Ramirez-Perez F., Smith J., et al. Neuraminidase inhibition improves endothelial function in diabetic mice. Am J Physiol Heart Circ Physiol. 2023. 325 (6): 1337–1353. doi:10.1152/ajpheart.00337.2023.Guo Z., Tuo H., Tang N., et al. Neuraminidase 1 deficiency attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory via AMPK-SIRT3 pathway in diabetic cardiomyopathy mice. Int J Biol Sci. 2022. 18 (2): 826–840. doi:10.7150/ijbs.65938.Guo Z., Tuo H., Tang N., et al. Neuraminidase 1 deficiency attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory via AMPK-SIRT3 pathway in diabetic cardiomyopathy mice. Int J Biol Sci. 2022. 18 (2): 826–840. doi:10.7150/ijbs.65938.

The authors declare that there are no conflicts of interest present.